{"id":14,"date":"2016-02-09T14:06:03","date_gmt":"2016-02-09T14:06:03","guid":{"rendered":"http:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/?p=14"},"modified":"2022-04-13T13:59:11","modified_gmt":"2022-04-13T13:59:11","slug":"fragmatic","status":"publish","type":"post","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/fragmatic\/","title":{"rendered":"FRAGMATIC: Results of the Largest UK Trial of Lung Cancer Patients with Low Molecular Weight Heparin"},"content":{"rendered":"

The results of the Fragmatic trial were recently published in the Journal of Clinical Oncology. The trial was funded by Cancer Research UK with support from Pfizer to answer this question: \u2018Should all newly diagnosed people with lung cancer be offered daily injections of a drug called dalteparin for six months to improve survival and prevent blood clots.\u2019 <\/em><\/p>\n

One of the paper’s authors, Fergus Macbeth, reflects on the importance\u00a0of the research.<\/em><\/p>\n

In 2005 the results from small trials in patients with small cell lung cancer, supported by indirect evidence from large trials including patients with a variety of cancers, suggested that giving drugs that prevent clots might improve survival. Patients with lung cancer are more at risk of blood clot, especially when having surgery or chemotherapy.<\/p>\n

Laboratory studies also suggested that a specific class of these drugs, heparins, might prevent the formation and growth of metastases (cancer spread). We therefore thought there might be two ways in which dalteparin (a form of heparin) might prevent serious problems: it might prevent fatal blood clots in patients at high risk and it might prevent the spread of cancer. But this theory needed to be tested with a large randomised trial.<\/p>\n

So we designed the trial to include newly diagnosed lung cancer patients of any type and extent of spread who, if they consented to enter the trial, would receive either daily injections of dalteparin for 26 weeks or no dalteparin in addition to their standard treatment. Patients, or relatives, were trained to give the injections themselves.<\/p>\n

Over 4 years, we recruited 2,202 patients from centres all around the UK, making this one of the largest ever randomised trials in lung cancer patients. When we analysed the results we found that there was no difference in the number of patients alive at the end of one year following diagnosis and there was no suggestion that those who received dalteparin were living longer. The risk of developing a potentially serious blood clot was reduced by half in those having dalteparin but the risk was lower than we expected (10%) and there was an increase in the risk of bleeding problems.<\/p>\n

When we looked a specific groups of patients (including those with small cell lung cancer) there was no suggestion that any group might be benefitting from the treatment. We tried to get a broadly representative group of lung cancer patients, but there were very few who had surgery and none who were very ill at the time of diagnosis. So it is still possible that are groups of patients who might benefit from routine use of dalteparin or similar drugs.<\/p>\n

Although the results of this trial may seem disappointing and \u2018negative\u2019, they are, however, very important. This is the first trial large enough to answer this question for any tumour type and does give a very clear result. So teams around the world may have to rethink their research strategies in this area.<\/p>\n

We are very grateful to all the patients, doctors and nurses and staff of the Wales Cancer Trials Unit who helped make this trial a success and to Cancer Research UK for providing the funding.<\/p>\n","protected":false},"excerpt":{"rendered":"The results of the Fragmatic trial were recently published in the Journal of Clinical Oncology. The trial was funded by Cancer Research UK with support from Pfizer to answer this […]","protected":false},"author":549,"featured_media":9,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[3],"tags":[48],"class_list":["post-14","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer-trial","tag-cancer"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7dIou-e","jetpack-related-posts":[{"id":152,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/pin-a-trial-looking-at-olaparib-for-non-small-cell-lung-cancer\/","url_meta":{"origin":14,"position":0},"title":"PIN: A Trial Looking At Olaparib For Non Small Cell Lung Cancer","author":"Joanna Canham","date":"April 13, 2016","format":false,"excerpt":"In 2013, there were 45,525 new cases of lung cancer in the UK and it kills around 35,000 annually (Source: CRUK). Non-small cell lung cancer (NSCLC) accounts for around 87% of all lung cancer. NSCLC is one of the leading causes of death worldwide and presents a huge health economic\u2026","rel":"","context":"In "Cancer Trial"","block_context":{"text":"Cancer Trial","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/cancer-trial\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/030914_7508-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":186,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/scope2-can-increasing-the-dose-of-radiotherapy-improve-outcomes-in-patients-with-oesophageal-cancer\/","url_meta":{"origin":14,"position":1},"title":"SCOPE2: Can Increasing The Dose Of Radiotherapy Improve Outcomes In Patients With Oesophageal Cancer?","author":"Ruby Ray","date":"April 26, 2016","format":false,"excerpt":"SCOPE2 is a randomised Phase II\/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET). SCOPE2\u00a0is a Cancer Research UK\u00a0funded trial run by the Wales Cancer\u2026","rel":"","context":"In "Cancer Trial"","block_context":{"text":"Cancer Trial","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/cancer-trial\/"},"img":{"alt_text":"SCOPE2 Workshop delegates.","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/SCOPE2-Workshop.jpeg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/SCOPE2-Workshop.jpeg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/SCOPE2-Workshop.jpeg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/04\/SCOPE2-Workshop.jpeg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":2693,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/world-radiography-day-2023-centre-for-trials-research-radiotherapy-trials-and-beyond\/","url_meta":{"origin":14,"position":2},"title":"World Radiography Day 2023: Centre For Trials Research Radiotherapy Trials And Beyond","author":"Sarah Bridges","date":"November 7, 2023","format":false,"excerpt":"Authors: Sarah Bridges, Christie Heiberg, Lisette Nixon, Jack Pritchard, Ann White BACKGROUND World Radiography Day marks the anniversary of the discovery of x-rays by Wilhelm Roentgen in 1895.\u00a0Soon after Roentgen\u2019s discovery, scientists began experimenting with x-rays on living tissue, learning that they were an effective method of stopping cancer cells\u2026","rel":"","context":"In "Events"","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/RT-blog-pic-1.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":2089,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/vim-abstract-at-asco-2021\/","url_meta":{"origin":14,"position":3},"title":"VIM Abstract At ASCO 2021","author":"Richard Haggerty","date":"June 7, 2021","format":false,"excerpt":"Professor Dean Fennell\u00a0(Chief Investigator for VIM) presented results of the ground-breaking, investigator-led trial at the ASCO global conference on Sunday 6th June 2021. Centre for Trials Research are supporting VIM. The prestigious ASCO accepted an abstract of the primary results data submitted earlier this year. ASCO ASCO is the American\u2026","rel":"","context":"In "Events"","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/06\/ASCO.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/06\/ASCO.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/06\/ASCO.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/06\/ASCO.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/06\/ASCO.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2021\/06\/ASCO.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":2734,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/faktion-and-the-breast-cancer-drug-paving-a-future-for-hormonal-therapies\/","url_meta":{"origin":14,"position":4},"title":"FAKTION And The Breast Cancer Drug Paving A Future For Hormonal Therapies","author":"Margherita Carucci","date":"November 29, 2023","format":false,"excerpt":"- by Margherita Carucci and Angela Casbard on behalf of the FAKTION CTR Team When a patient is diagnosed with cancer, their doctor will prescribe a drug or a combination of drugs for destroying or keeping the cancer cells under control. But how do doctors know which drugs are the\u2026","rel":"","context":"In "Events"","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2023\/11\/Breast-Cancer-Breakthrough-The-FAKTION-Trials-Pioneering-Findings-at-ASCO.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":2896,"url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/the-piccos-study-evaluating-anti-cancer-drug-delivery\/","url_meta":{"origin":14,"position":5},"title":"The PICCOS Study: Evaluating Anti-Cancer Drug Delivery","author":"Rebecca Hamilton","date":"April 24, 2024","format":false,"excerpt":"Study Name: Pressurised IntraPeritoneal Aerosolised Chemotherapy (PIPAC) in the management of cancer of the colon, ovary and stomach: a randomised controlled phase II trial of efficacy in peritoneal metastases (PICCOS for short). Background The study is funded by NIHR EME (Efficacy and Mechanism Evaluation) Programme Grant to treat patients with\u2026","rel":"","context":"In "Events"","block_context":{"text":"Events","link":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/category\/events\/"},"img":{"alt_text":"PIPAC training image","src":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/04\/PIPAC-training-image.jpeg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/04\/PIPAC-training-image.jpeg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/04\/PIPAC-training-image.jpeg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/04\/PIPAC-training-image.jpeg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2024\/04\/PIPAC-training-image.jpeg?resize=1050%2C600&ssl=1 3x"},"classes":[]}],"meta_box":[],"jetpack_featured_media_url":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-content\/uploads\/sites\/499\/2016\/02\/030914_7609-scaled.jpg","_links":{"self":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/14","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/users\/549"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/comments?post=14"}],"version-history":[{"count":6,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/14\/revisions"}],"predecessor-version":[{"id":533,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/posts\/14\/revisions\/533"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/media\/9"}],"wp:attachment":[{"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/media?parent=14"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/categories?post=14"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.cardiff.ac.uk\/centre-for-trials-research\/wp-json\/wp\/v2\/tags?post=14"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}